Advances and Trends
in Hormonal Therapy for
Advanced Prostate Cancer

Debruyne, F.M.J.; Dijkman, G.A.

doi:10.1159/000475049

Cited by 24 publications

(20 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Luteinizing hormone-releasing hormone analogues (LH-RH-a) have now become established medication for the palliative treatment of advanced prostate cancer (PCa) and are equal to orchiectomy in terms of clinical effectiveness [1]. Injectable monthly depots have greatly contributed to their widespread use and acceptance as well as to patient compliance [2].…”

Section: Introductionmentioning

confidence: 99%

Comparison of LH-RH Analogue 1-Month Depot and 3-Month Depot by Their Hormone Levels and Pharmacokinetic Profile in Patients with Advanced Prostate Cancer

Tunn¹,

Bargelloni²,

Cosciani³

et al. 1998

Urol Int

View full text Add to dashboard Cite

In an open, randomized phase II pharmacokinetic study conducted in Germany and Italy, a total of 42 patients with advanced or metastatic prostate cancer (PCa) were treated for 9 months with the luteinizing hormone-releasing hormone analogue (LH-RH-a) leuprorelin acetate depot in two different formulations. Fifteen patients received the 1-month depot and 27 patients received the newly developed 3-month depot, containing 3.75 mg and 11.25 mg, respectively. In both groups, subcutaneous injections of leuprorelin acetate injected monthly or at 3-month intervals produced a complete down-regulation of the pituitary and led to persistent suppression of testosterone and dihydrotestosterone to the castrate range (≤50 ng/dl for testosterone) within the first month of treatment, which thereafter could be maintained over the entire observation period of 9 months. In 10 patients, pretreatment with an antiandrogen for the prevention of clinical flare-up resulted in a slightly more profound and earlier drop in serum testosterone. The 3-month depot showed a higher median peak serum concentration (C_max) of leuprorelin at 20.8 ng/ml than the 1-month depot at 10.7 ng/ml but, conversely, this did not influence the rise in serum testosterone levels. C_max occurred at 3 h for the 3-month and at 1 h for the 1-month depot formulation. During the steady state, constant release could be detected, starting on day 3 and day 7 for the 1-month and 3-month depot, respectively. A marked decrease in median prostate-specific antigen levels of 97.8% (1-month depot) and 96.6% (3-month depot) compared with baseline was observed, indicating an objective clinical response for more than 80% of all patients in both arms. Based on European Organization for Research and Treatment of Cancer criteria, the best response in terms of complete/partial remissions and stabilization was comparable in the two arms at 86.7% (1-month depot) and 85.2% (3-month depot). 6.7% in the 1-month group and 3% in the 3-month depot group showed progression of the disease. The most common side effects in both treatment groups were related to hormone deprivation. Both formulations of the potent LH-RH-a leuprorelin acetate were highly effective in the treatment of advanced PCa and led to comparable endocrine and clinical effects.

show abstract

Section: Introductionmentioning

confidence: 99%

Comparison of LH-RH Analogue 1-Month Depot and 3-Month Depot by Their Hormone Levels and Pharmacokinetic Profile in Patients with Advanced Prostate Cancer

Tunn¹,

Bargelloni²,

Cosciani³

et al. 1998

Urol Int

View full text Add to dashboard Cite

show abstract

“…Where an antiandrogen is used, in associa tion with castration, the inhibition of androgens of adre nal origin associated to castration realise the so-called complete androgen blockade (CAB) [2,3], Compared with castration alone, CAB has been shown in three large, prospective, randomised trials in stage D2 patients to offer advantages in terms of survival and disease free pro gression [4][5][6]. However, many other, often smaller, stud ies have not shown any advantages for CAB.…”

Section: Boccon-gibodmentioning

confidence: 99%

Introduction

Boccon-Gibod¹

1997

Eur Urol

View full text Add to dashboard Cite

“…Castration can be performed either surgically by stan dard or subcapsular orchidectomy, or medically using luteinizing hormone (LH)-releasing hormone (LHRH) indeed lead to treatment suspension in 5-20% of patients, and the results from a well-designed prospective study suggest that bicalutamide is associated with the lowest rate of side-effect-induced treatment cessation [6,7].…”

Section: Castrationmentioning

confidence: 99%

Maximum Androgen Blockade in 1996

Boccon-Gibod

1996

Eur Urol

View full text Add to dashboard Cite

Advances and Trends in Hormonal Therapy for Advanced Prostate Cancer

Cited by 24 publications

References 49 publications

Comparison of LH-RH Analogue 1-Month Depot and 3-Month Depot by Their Hormone Levels and Pharmacokinetic Profile in Patients with Advanced Prostate Cancer

Comparison of LH-RH Analogue 1-Month Depot and 3-Month Depot by Their Hormone Levels and Pharmacokinetic Profile in Patients with Advanced Prostate Cancer

Introduction

Maximum Androgen Blockade in 1996

Contact Info

Product

Resources

About